Carbimazole: increased risk of congenital malformations; strengthened advice on contraception

Carbimazole is associated with an increased risk of congenital malformations, especially when administered in the first trimester of pregnancy and at high doses.

Carbimazole: risk of acute pancreatitis

If acute pancreatitis occurs during treatment with carbimazole, immediately and permanently stop treatment.

SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)

If Fournier’s gangrene is suspected, stop the SGLT2 inhibitor and start treatment urgently (including antibiotics and surgical debridement).

Letters and drug alerts sent to healthcare professionals in January 2019

Letters were sent to healthcare professionals about Lartruvo▼ (olaratumab), quadrivalent influenza vaccine (split virion, inactivated), SGLT2 inhibitors, and carbimazole and thiamazole (synonym: methimazole)-containing products. Class 2 medicines recalls were issued for batches of irbesartan/hydrochlorothiazide and irbesartan tablets.

Medical Device Alerts issued in January 2019

Alerts were issued about FreeStyle Libre flash glucose sensors and Arjo Minstrel passive floor lifts (portable hoist).

Posted on the UK MHRA website on 18 February 2019